- Phase I
- Phase II/III
- Therapeutic expertise
- Rescue services
- Technology solutions
- Comprehensive capabilities
- News &
Atopic Dermatitis and Vaccinia Immunization Network (ADVN)
Helping develop safer vaccines for patients at risk
The Atopic Dermatitis and Vaccinia Immunization Network (ADVN) sponsored by the National Institutes of Allergy and Infectious Diseases (NIAID) comprises a Clinical Studies Consortium, an Animal Studies Consortium, and a Statistical and Data Coordinating Center (SDCC). The primary goal of the ADVN is to advance clinical research in the development of safer smallpox vaccines for individuals with atopic dermatitis (AD). People with atopic dermatitis should not receive the smallpox immunization because of increased risk of a serious and potentially fatal complication called eczema vaccinatum. Data from this research will form the basis for new diagnostic and therapeutic approaches to reduce the prevalence of eczema vaccinatum following smallpox vaccination.
Rho serves as the SDCC for the ADVN, providing support for the network’s clinical and animal study consortium. In this capacity, Rho is responsible for statistical and data analysis, clinical coordination, regulatory guidance, computer-based data collection and management, operational support, and the establishment and maintenance of a registry of patients with atopic dermatitis.
Gloria David, Ph.D., M.H.Sc., is Principal Investigator (PI) of the ADVN SDCC. As a post-doctoral fellow for both the Johns Hopkins Department of Oncology and the National Institute of Environmental Health Sciences, Dr. David has received numerous professional honors for accomplishments in cancer research and respiratory disease. She is lead author in many peer-reviewed publications for research in lung, prostate, and breast cancer, asthma, and other respiratory diseases. Karen Kesler, Ph.D., Assistant Director of Biostatistics, is the co-PI for this research program.
For more information about this research from ClinicalTrials.gov, please see below.